H-IE is in progress, with a view to prevention of West syndrome by early administration of ACTH [Millichap JJ, prepublication observations].

References

LONG-TERM OUTCOME OF JUVENILE MYOCLONIC EPILEPSY

Investigators at Epilepsy Centers in Berlin, Germany, performed a retrospective study of seizure outcome in 66 patients with juvenile myoclonic epilepsy (JME) after a mean follow-up time of 44.6 years (20-69 years); 59.1% of patients remained seizure-free for at least 5 years before the last contact. Of seizure-free patients, 28 (71.8%) remained on AEDs and 11 (28.2%) were off medication for at least the last 5 years. Absence seizures at onset were an independent predictor of an unfavorable outcome and JME persistence. (Senf P, et al. Prognosis of juvenile myoclonic epilepsy 45 years after onset. Seizure outcome and predictors. Neurology 2013 Dec 10;81(24):2128-33).

COMMENTARY. JME is usually described as a chronic disorder requiring lifelong therapy [1]. In contrast, recent long-term follow-up studies point to a more favorable prognosis, allowing cautious withdrawal of medication after long seizure control [2]. In an editorial comment, a trial of older medications, including primidone and acetazolamide, is recommended in patients with refractory JME [3].

References

ENCEPHALOPATHIES

ENCEPHALOPATHIC SUSAC SYNDROME

Investigators from Tubingen and Munster, Germany, report the case of a 32-year-old woman who at 32 weeks of pregnancy developed a change in personality, disorientation, ataxia, dysarthria, and hemispasticity. MRI showed multiple diffuse T2-intense lesions, many involving the corpus callosum. CSF showed mild lymphocytic pleocytosis (13 cells/mcl) and elevated protein (1,800 mg/l) and no oligoclonal bands. A bluish, net-like exanthema on trunks and legs was diagnosed as livedo racemosa. Weeks later, she was readmitted with visual field loss and ischemic damage to both retinae, and bilateral hearing loss. With a diagnosis of Susac syndrome, IV cyclophosphamide, the standard treatment, was not instituted because of risk of permanent infertility. A combination of prednisolone, IV immunoglobulins, mycophenolate mofetil, and methotrexate provided a sustained control of symptoms. (Engeholm M, et al.

COMMENTARY. Susac syndrome (SS)[1] consists of a triad of encephalopathy, branch retinal artery occlusions and hearing loss. Associated abnormalities include multifocal corpus callosal lesions on MRI [2], resembling a vasculitis, and autoimmune disorder such as juvenile dermatomyositis. Headache is usually constant but was absent in the above case. Women are affected more often than men (3:1); the age of onset ranges from 7 to 72 years, but ages 20-40 are most vulnerable [3]. SS is an autoimmune endotheliopathy that responds to treatment with immunosuppressants, steroids, cyclophosphamide, and IV immunoglobulin, with aspirin as an adjunct [2][4].

References

INTERFERON BIOMARKERS IN AICARDI-GOUTIERES SYNDROME

Investigators at University of Manchester, UK, and multiple international centers studied interferon-related biomarkers in patients with Aicardi-Goutieres syndrome (AGS). Of 82 patients with AGS, 74 (90%) had a positive interferon score. The measurement of an interferon score might be used to assess efficacy of anti-inflammatory therapy. (Rice GI, Forte GMA, Szynkiewicz M, et al. Assessment of interferon-related biomarkers in Aicardi-Goutieres syndrome associated with mutations in TREX1 (and any of six genes): a case-control study. Lancet Neurol 2013 Dec;12(12):1159-69).

COMMENTARY. Aicardi-Goutieres syndrome is an early-onset familial encephalopathy characterized by brain atrophy, microcephaly, spasticity, dystonia, psychomotor retardation, chronic CSF lymphocytosis, basal ganglia calcification, autoimmune disorders such as chilblains (pernio), and increased interferon-alpha in the CSF and serum [1][2]. High mortality in the first year is common. An early active stage of the disease followed by a period of attenuation correlates with higher levels of interferon activity in infancy and lower levels with increasing age.

References.